Program
Dimethyl Fumarate
Also written as “dimethyl fumarate”, “BG00012” and “FP187”.
Its studies are mostly in Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis · Psoriasis · Multiple Sclerosis, Chronic Progressive · Arthritis, Rheumatoid, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biogen | 331 open or running | phase 4since May 9, 2013 | Sep 9, 2005 | Jul 28, 2034phase 3 · NCT07483632 |
| Almirall | 20 open or running | phase 3since Nov 12, 2012 | Nov 12, 2012 | none ahead |
| Forward-Pharma | 20 open or running | phase 3since Mar 19, 2013 | Sep 24, 2010 | none ahead |
Also a collaborator on its studies: gb-pharma-services-consulting-s-r-l, almirall-hermal-gmbh and harrison-clinical-research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Sep 9, 2005.
- Jun 20, 2014Phase 1 study in HealthyBiogen · NCT02171208 · 80 enrolled · United States
- Nov 3, 2014Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02283853 · 156 enrolled · United States, Belgium, Bulgaria and more
- Jan 9, 2015Phase 4 study in Multiple SclerosisBiogen · NCT02343159 · 84 enrolled · United States
- Apr 2, 2015Phase 2 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02410200 · 22 enrolled · United States, Belgium, Bulgaria and more
- Apr 23, 20153 phase 3 studiesBiogen · NCT02428231, NCT02428218, NCT02430532
- May 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02472938
- Jun 11, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02471560 · 36 enrolled · Norway
- Jul 10, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02525874 · 218 enrolled · United States, Belgium, Bulgaria and more
- Sep 17, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02555215 · 20 enrolled · United States, Belgium, Bulgaria and more
- Oct 16, 2015Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT02579681 · 221 enrolled · Italy
- Oct 25, 2016Phase 1 study in PsoriasisAlmirall · NCT02955693 · 32 enrolled · United Kingdom
- Mar 7, 2019Phase 3 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT03870763 · 11 enrolled · United States, Colombia, Estonia and more
- Dec 12, 2022Phase 4 study in Multiple SclerosisBiogen · NCT05658484 · 60 enrolled · China
- Feb 26, 2026Phase 3 study in Relapsing Forms of Multiple SclerosisBiogen · NCT07483632 · 185 planned
Ahead
- Jul 28, 2034Primary completion: phase 3 study in Relapsing Forms of Multiple SclerosisBiogen · NCT07483632
TargetBeta
“Kelch-like ECH-associated protein 1 inhibitor”ChEMBL 37, by rule
Other programs on KEAP1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| diroximel fumaraterule | Biogen | phase 3 | 5 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07483632Relapsing Forms of Multiple Sclerosis | 3 | Not yet recruiting | Biogen | Jul 28, 2034 | 185 |
| NCT05658484Multiple Sclerosis · China | 4 | Completed | Biogen | Mar 27, 2025 | 60 |
| NCT03870763Multiple Sclerosis, Relapsing-Remitting · United States, Colombia, Estonia and more | 3 | Terminated | Biogen | Jul 21, 2022 | 11 |
| NCT02955693Psoriasis · United Kingdom | 1 | Completed | Almirall | Oct 2016 | 32 |
| NCT02579681Multiple Sclerosis, Relapsing-Remitting · Italy | 3 | Completed | Biogen | Dec 21, 2016 | 221 |
| NCT02555215Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 3 | Completed | Biogen | Sep 24, 2018 | 20 |
| NCT02525874Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 3 | Completed | Biogen | Apr 24, 2017 | 218 |
| NCT02471560Multiple Sclerosis, Relapsing-Remitting · Norway | 4 | Completed | Biogen | Jun 12, 2017 | 36 |
| NCT02472938Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Jul 2019 | 0 |
| NCT02430532Multiple Sclerosis, Chronic Progressive · United States, Belgium, Czech Republic and more | 3 | Terminated | Biogen | Jan 2016 | 58 |
| NCT02428231Multiple Sclerosis · United States, Belgium, Czech Republic and more | 3 | Terminated | Biogen | Dec 2015 | 62 |
| NCT02428218Multiple Sclerosis, Relapsing-Remitting | 3 | Withdrawn | Biogen | Jan 2027 | 0 |
| NCT02410200Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 2 | Completed | Biogen | Sep 23, 2016 | 22 |
| NCT02343159Multiple Sclerosis · United States | 4 | Terminated | Biogen | Apr 15, 2016 | 84 |
| NCT02283853Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 3 | Completed | Biogen | Jul 8, 2025 | 156 |
| NCT02171208Healthy · United States | 1 | Completed | Biogen | Jul 2014 | 80 |
| NCT02125604Multiple Sclerosis, Relapsing-Remitting · Germany | 4 | Completed | Biogen | Feb 2016 | 214 |
| NCT02097849Relapsing Forms of Multiple Sclerosis · United States | 2 | Completed | Biogen | May 2, 2016 | 71 |
| NCT02090348Multiple Sclerosis, Relapsing-Remitting | 4 | Withdrawn | Biogen | Oct 2017 | 0 |
| NCT01930708Multiple Sclerosis, Relapsing-Remitting · Austria, Belgium, Canada and more | 4 | Completed | Biogen | Mar 31, 2016 | 1,114 |
| NCT01924832Healthy · United Kingdom | 1 | Completed | Biogen | Apr 2014 | 32 |
| NCT01873417Relapsing Forms of Multiple Sclerosis · United States | 4 | Completed | Biogen | Nov 2013 | 237 |
| NCT01838668Multiple Sclerosis, Relapsing-Remitting · Czechia, Japan, Korea, Republic of and more | 3 | Completed | Biogen | Jun 16, 2015 | 225 |
| NCT01815723Psoriasis · Canada | 3 | Withdrawn | Forward-Pharma | Jun 2017 | 0 |
| NCT01726933Psoriasis · Austria, Germany, Netherlands and more | 3 | Completed | Almirall | Oct 2014 | 839 |
| NCT01568112Healthy · United States | 3 | Completed | Biogen | Oct 2012 | 173 |
| NCT01453426Healthy · Australia, China | 1 | Completed | Biogen | Apr 2012 | 71 |
| NCT01281111Healthy · United States | 1 | Completed | Biogen | Mar 18, 2011 | 56 |
| NCT01230138Plaque Psoriasis · Germany | 2 | Completed | Forward-Pharma | Jan 2012 | 252 |
| NCT01156311Multiple Sclerosis, Relapsing-Remitting · United States | 2 | Completed | Biogen | Mar 2012 | 108 |
| NCT01069913Healthy | 1 | Completed | Biogen | Oct 2009 | 14 |
| NCT00837785Multiple Sclerosis, Relapsing-Remitting · Germany | 1 | Completed | Biogen | Oct 31, 2009 | 48 |
| NCT00835770Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more | 3 | Completed | Biogen | Nov 8, 2019 | 1,736 |
| NCT00810836Arthritis, Rheumatoid · Australia, Canada, Czech Republic and more | 2 | Completed | Biogen | Feb 2010 | 153 |
| NCT00451451Multiple Sclerosis, Relapsing-Remitting · United States, Belarus, Belgium and more | 3 | Completed | Biogen | Aug 2011 | 1,417 |
| NCT00420212Multiple Sclerosis, Relapsing-Remitting · United States, Australia, Austria and more | 3 | Completed | Biogen | Feb 2011 | 1,234 |
| NCT00168701Multiple Sclerosis · Czechia, Germany, Hungary and more | 2 | Completed | Biogen | Mar 31, 2006 | 260 |
How it is read
Names in the registry
- “dimethyl fumarate”, 19 entries
- “BG00012”, 8 entries
- “FP187”, 5 entries
- “Dimethyl Fumarate”, 2 entries
- “Dimethyl fumarate”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, Relapsing-Remitting, 18 studies
- Multiple Sclerosis, 7 studies
- Psoriasis, 4 studies
- Multiple Sclerosis, Chronic Progressive, 1 study
- Arthritis, Rheumatoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.